Framycetin, a broad-spectrum amino glycoside antibiotic,
is usually bactericidal in action. Although the exact mechanism of action
has not been fully elucidated, the drug appears to inhibit protein synthesis
in susceptible bacteria by binding to ribosomal subunits. In general,
framycetin is active against many aerobic gram-negative bacteria and
some aerobic gram-positive bacteria. The drug is inactive against fungi,
viruses, and most anaerobic bacteria.
Gramicidin is a cyclic polyceptide antibiotic. It alters
the cation content of the bacterial cell wall. Gramicidin is primarily
effective against gram-positive organisms.
For local use in the treatment of infections caused by pyogenic organisms, in particular S. aureus, the proteus group of bacteria, coliforms and P. aeruginosa.
The treatment of bacterial infections of the skin and mucous membrane caused by susceptible bacteria. These include such conditions as pyoderma, folliculitis, paronychia, sycosis barbae, and impetigo. Also useful in controlling secondary bacterial infections in skin carcinoma, burns, eczemas, contact dermatitis, seborrhea, acne, psoriasis, varicose ulcers, and neurodermatitis.
Sensitivity to framycetin. Framycetin should never be administered either i.v. or i.m. in view of the risk of irreversible ototoxicity or reversible nephrotoxicity.
Cross sensitization may occur among the group of Streptomyces derived antibiotics (neomycin, paromomycin, kanamycin) of which framycetin is a member, but this is not invariable. Prolonged use of antibiotics may result in the overgrowth of nonsusceptible organisms, including fungi. Appropriate measures should be taken if this occurs.
DOSAGE AND ADMINISTRATION
Apply locally 2 to 4 times a day as prescribed.
AVAILABILITY OF DOSAGE FORMS
Each g of ointment contains: framycetin sulfate BP 15 mg (1.5%), gramicidin 50 µg (0.005%) and anhydrous lanolin 10%. Tubes of 15 g.